Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
about
BRCA2 suppresses replication stress-induced mitotic and G1 abnormalities through homologous recombination.Current status of poly(ADP-ribose) polymerase inhibitors and future directions.Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors.Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and CancerTargeted treatment of advanced ovarian cancer: spotlight on rucaparibMethylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
P2860
Q41125254-ADB572B5-B944-4126-9546-0A5D00D40987Q47155297-16C9DADF-8716-4038-9AC9-9FBE6B2A774FQ48352256-4235C8AF-AC80-48BA-811F-47BDF36B26EDQ49723005-0DCCB73E-C9AC-4276-9A37-EADEF1D2477BQ50088520-2C512AC4-1337-49DE-B5FB-A9242D2728FAQ52430620-28302F3A-E81F-4DFA-A104-D23DECAEA13DQ54935812-32998677-EF4F-497E-BD13-90EC69FA2B9FQ55211683-47BAA9F3-AAA7-41A8-AD89-7EBE1690771DQ55230708-67A399C7-5A3F-4944-8BEC-514FD3599B36Q57826033-449D0393-9ED6-47C3-BCDE-7CA6A730A212Q59125756-180AEFA3-F6A8-49E8-AB00-FB385954A594Q59126243-CE1521FB-C4CE-4E99-ADBB-5B0D14EB83ED
P2860
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Secondary Somatic Mutations Re ...... High-Grade Ovarian Carcinoma.
@en
type
label
Secondary Somatic Mutations Re ...... High-Grade Ovarian Carcinoma.
@en
prefLabel
Secondary Somatic Mutations Re ...... High-Grade Ovarian Carcinoma.
@en
P2093
P2860
P50
P1433
P1476
Secondary Somatic Mutations Re ...... High-Grade Ovarian Carcinoma.
@en
P2093
AOCS Study Group
Andrew D Simmons
Anna V Tinker
Anne Floquet
Clare L Scott
David M O'Malley
Elizabeth M Kass
Elizabeth M Swisher
Ganessan Kichenadasse
P2860
P304
P356
10.1158/2159-8290.CD-17-0419
P50
P577
2017-06-06T00:00:00Z